Chugai Pharmaceutical (4519 JP) shares declined 5% since I published initial bearish note on the company in December. I remain bearish on the name.
Despite a 60% y/y jump in revenue in Q1 2022, the company is still guiding for just 15% y/y revenue growth in 2022. Operating margin has deteriorated in Q1.
Chugai’s significant dependency on COVID-19 drugs amid declining new infections and hospitalizations globally, remain the major overhang on the growth prospects of the company.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.